Performance of a new *Candida* anti-mannan IgM and IgG assays in the diagnosis of candidemia

Yanming Meng, Mei Kang, Dongdong Li, Tingting Wang, Ziwei Kuang, Ying Ma

**ABSTRACT**

*Candida* is one of the most frequent pathogens of bloodstream infections, which is associated with high morbidity and mortality rates. Rapid immunological detection methods are essential in the early diagnosis of candidemia. Anti-mannan is one of host-derived biomarkers against cell wall components of *Candida*. We conducted this study to evaluate the diagnostic performance of two anti-mannan assays (IgM, IgG) for candidemia through the analysis of 40 candidemia patients, 48 participants with *Candida* colonization and 213 participants with neither *Candida* colonization nor *Candida* infections (13 patients with other bloodstream infections, 145 hospitalized patients and 55 healthy controls). The performance of the two assays were evaluated by calculating their sensitivity and specificity. The sensitivity ranged from 0.78 to 0.80 for the IgM assay and 0.68 to 0.75 for the IgG assay. The specificity ranged from 0.97 to 0.98 for the IgM assay and 0.91 to 0.94 for the IgG assay. The diagnostic performance of the anti-mannan IgM assay was better than that of IgG, with higher sensitivity and specificity. Combining the two assays (positive results of single or both assays are both considered as positive) could improve the sensitivity up to 0.93 (0.79-0.98) and only slightly reduce the specificity (0.93(0.89-0.95)). The anti-mannan IgM, IgG assays are rapid and cost-effective assays that may be probably useful in the diagnosis of candidemia.

**KEYWORDS:** Candidemia. Anti-mannan. Diagnosis.

**INTRODUCTION**

*Candida* is one of the leading causes of healthcare-associated bloodstream infections. Owing to the advances in medical technology, the application of invasive procedures is becoming more and more extensive, increasing significantly the burden of *Candida* infections, especially in critically ill patients. Early initiation of effective antifungal therapy was essential to improve the outcome of patients, while misdiagnosis or delay in diagnosis of candidemia could result in substantial morbidity and mortality (as high as 46–75%), so the early diagnosis of candidemia is of great value.

Blood cultures are the gold standard of candidemia’s diagnosis. The current guidelines provided by the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) and the Infectious Diseases Society of America (IDSA) have shown that it is essential to draw at least two pairs of blood cultures for the diagnosis of candidemia. The frequency recommended was daily and the incubation period was at least 5 days. When all these recommendations are followed, sensitivity of blood cultures to detect *Candida* will be between 50–75%. The sensitivity will further decrease when detecting patients who have neutropenia or...
previous antifungal treatment. In addition, its turnaround time was limited so it cannot be considered as an early diagnostic technique. Regarding the clinical use of some biomarkers, B-D-glucan, mannan and anti-mannan are recommended with levels of evidence being II (second) according to ESCMID guidelines for Candida diseases.

The Dynamiker Candida anti-mannan IgM and IgG assays are new enzyme-linked immunosorbent assays (ELISA) designed to rapidly identify antigens from Candida’s cell wall in serum samples. This study evaluated the performance of two different antibody isotypes for diagnosis of candidemia.

**MATERIALS AND METHODS**

**Study population**

This study was approved by the Ethics Committee of the West China Hospital, (The Ethics Committee of West China Hospital, N° 75, 76). To assess the diagnostic performance of the new anti-mannan IgM, IgG antibody assays, three groups of cases were enrolled: (1) Culture-confirmed candidemia, (2) Candida colonization without infection, (3) Neither Candida colonization nor infections.

Candidemia was defined as the presence of one or more Candida species in the bloodstream. Its diagnostic criteria were at least one positive blood culture that yielded at least one of the Candida species in patients with consistent clinical manifestations. The exclusion criteria were as follows: neutropenia (total leukocyte count \( \leq 500/\text{mm}^3 \)), pregnancy, autoimmune diseases, recent or ongoing immunosuppressive or antifungal therapy, significantly abnormal immune function. The blood cultures were processed by the BacTAlert® Virtuo® (bioMérieux, Marcy l’Etoile, France) system. All the specimens with positive results of blood cultures were identified on microscopy and subcultured on blood agar and chocolate agar for 48 h at 35 °C under aerobic conditions. Candida spp. isolated from blood samples underwent identification by MALDI-TOF mass spectrometry.

Candida colonization was defined as the recovery of Candida spp. from nonsterile and noncontiguous sites including mouth, throat, bronchus, skin and urethra. In the present study, we only enrolled cases who have Candida colonization in the upper respiratory tract because it is the most common colonization site. The exclusion criteria were: positive blood cultures for Candida; neutropenia; antifungal/immunosuppressive therapy; positive (1-3)-β-D-Glucan.

In total, there were 213 cases with neither colonization nor infections, 48 with Candida colonization and 40 with candidemia in our study. Among the cases with neither Candida colonization nor infections, 55 of them were healthy controls randomly selected from the health examination center of the West China Hospital, 158 were hospitalized patients, of whom 13 had other bloodstream infections. The 13 patients included 4 with Staphylococcus spp., 2 with Enterobacteria spp., 1 with Enterococcus spp., 1 with Talaromyces (Penicillium) marneffei, and 5 with Cryptococcus spp. infection. None of them had neutropenia, recent or ongoing immunosuppressive therapy or antifungal therapy.

The baseline characteristics of the 40 candidemia patients were presented in Table 2, while characteristics of control group 1 (neither Candida colonization nor infections group) and control group 2 (Candida colonization group) were presented in Table 3.

**ELISA assay**

The new anti-mannan IgM and IgG assays (Dynamiker Biotechnology, Tianjin, China) were performed strictly according to the manufacturer’s instructions. The

| Diagnostic parameter | Value of different anti-mannan antibody isotypes |
|----------------------|------------------------------------------------|
|                      | anti-mannan IgM | anti-mannan IgG | anti-mannan IgM+IgG |
| **Sensitivity (% [95% CI])** | | | |
| Candida colonization | 0.78 (0.61-0.89)a | 0.68 (0.51-0.81)a | 0.93 (0.79-0.98) |
| Neither colonized nor infected | 0.80 (0.64-0.90)b | 0.75 (0.58-0.87)b |
| **Specificity (% [95% CI])** | | | |
| Candida colonization | 1 (0.91-1)a | 0.88 (0.74-0.95)a | 0.88 (0.74-0.95) |
| Neither colonized nor infected | 1 (0.91-1)b | 0.77 (0.77-0.87) |
| **Overall** | 0.97 (0.94-0.99)a | 0.96 (0.92-0.98)a | 0.94 (0.90-0.97) |
| | 0.97 (0.94-0.99)b | 0.94 (0.90-0.97)b |

*aUndetermined results (80-120 AU/mL) were considered as negative results; bUndetermined results were considered as positive results. CI- confidence interval.
Table 2 - Characteristics of the 40 blood culture-positive candidemia patients and detection of anti-mannan IgG and IgM antibodies results.

| Case Nº | Age | Sex | Underlying condition                  | Time of incubationa | Anti-mannan IgG concentration (AU/mL) | Anti-mannan IgG results | Anti-mannan IgM concentration (AU/mL) | Anti-mannan IgM results |
|---------|-----|-----|---------------------------------------|----------------------|--------------------------------------|------------------------|--------------------------------------|------------------------|
| 1       | 30  | F   | Heart failure                         | 1.58                 | 319.21                               | P                      | 189.91                               | P                      |
| 2       | 30  | M   | Acute pancreatitis                    | 2                    | 51.56                                | N                      | >500                                 | P                      |
| 3       | 29  | M   | Hematological system disease          | 0.95                 | 217.52                               | P                      | 147.56                               | P                      |
| 4       | 71  | M   | Postoperative infection               | 1.5                  | 150.88                               | P                      | >500                                 | P                      |
| 5       | 22  | M   | Aplastic anemia                       | 0.7                  | 190.33                               | P                      | 28.16                                | N                      |
| 6       | 45  | F   | Chronic hepatitis B                   | 0.81                 | 293.45                               | P                      | 336.08                               | P                      |
| 7       | 0   | F   | Postoperative infection               | 1.16                 | 39.80                                | N                      | >500                                 | P                      |
| 8       | 48  | M   | Acute pancreatitis                    | 2                    | 156.90                               | P                      | 425.57                               | P                      |
| 9       | 66  | F   | Chronic renal failure                 | 0.38                 | 135.45                               | P                      | 485.47                               | P                      |
| 10      | 0   | F   | Intestinal fistula                    | 2                    | 27.38                                | N                      | >500                                 | P                      |
| 11      | 66  | F   | Heart disease                         | 1.12                 | 173.98                               | P                      | 133.81                               | P                      |
| 12      | 78  | M   | Intracranial infection                | 1.34                 | 284.13                               | P                      | 212.53                               | P                      |
| 13      | 46  | M   | Heart disease                         | 2                    | 132.60                               | P                      | 198.82                               | P                      |
| 14      | 31  | M   | Acute pancreatitis                    | 1.12                 | 350.07                               | P                      | 131.89                               | P                      |
| 15      | 50  | M   | Cholecystolithiasis                   | 3.29                 | 30.30                                | N                      | 199.61                               | P                      |
| 16      | 40  | M   | Trauma                                | 1.7                  | 54.87                                | N                      | >500                                 | P                      |
| 17      | 68  | M   | Intestinal obstruction                | 1.5                  | >500                                 | P                      | 123.23                               | P                      |
| 18      | 63  | M   | Chronic obstructive pulmonary diseases| 1.29                 | 22.67                                | N                      | >500                                 | P                      |
| 19      | 76  | M   | Esophageal stricture                  | 1.75                 | 257.64                               | P                      | 382.81                               | P                      |
| 20      | 61  | F   | Arthritis                             | 1.18                 | 191.80                               | P                      | 208.57                               | P                      |
| 21      | 64  | F   | Trauma                                | 1.17                 | 186.36                               | P                      | 128.76                               | P                      |
| 22      | 75  | F   | Abnormal liver function               | 0.25                 | >500                                 | P                      | 23.94                                | N                      |
| 23      | 17  | M   | Trauma                                | 0.45                 | >500                                 | P                      | 23.21                                | N                      |
| 24      | 42  | F   | Acute pancreatitis                    | 1.63                 | 83.02                                | I                      | 176.67                               | P                      |
| 25      | 79  | M   | Intestinal obstruction                | 1.88                 | >500                                 | P                      | 29.20                                | N                      |
| 26      | 44  | M   | Pulmonary infection                   | 2.33                 | >500                                 | P                      | 61.04                                | N                      |
| 27      | 44  | F   | Hepatic abscess                       | 0.71                 | 58.41                                | N                      | 92.99                                | I                      |
| 28      | 48  | M   | Trauma                                | 0.8                  | 96.98                                | I                      | 264.82                               | P                      |
| 29      | 35  | M   | Abnormal liver function               | 2.2                  | >500                                 | P                      | 46.76                                | N                      |
| 30      | 20  | M   | Trauma                                | 1.38                 | 359.06                               | P                      | 199.61                               | P                      |
| 31      | 51  | M   | Cerebral hemorrhage                   | 0.7                  | 84.81                                | I                      | >500                                 | P                      |
| 32      | 33  | F   | Acute pancreatitis                    | 0.87                 | 54.20                                | N                      | 181.47                               | P                      |
| 33      | 49  | F   | Intestinal obstruction                | 1.58                 | 490.59                               | P                      | 345.08                               | P                      |
| 34      | 63  | M   | Heart disease                         | 2.29                 | 28.68                                | N                      | 20.58                                | N                      |
| 35      | 60  | M   | Trauma                                | 0.46                 | 288.87                               | P                      | >500                                 | P                      |
| 36      | 39  | M   | Anemia                                | 0.88                 | 380.88                               | P                      | 244.82                               | P                      |
| 37      | 62  | M   | None                                  | 1.17                 | 244.42                               | P                      | >500                                 | P                      |
| 38      | 56  | M   | Gastrointestinal perforation          | 1.12                 | 141.06                               | P                      | >500                                 | P                      |
| 39      | 37  | M   | Acute pancreatitis                    | 2.33                 | 337.44                               | P                      | 143.19                               | P                      |
| 40      | 59  | F   | Arterial embolism of lower extremities| 1.75                 | 42.64                                | N                      | 28.28                                | N                      |

aTotal incubation time to get a positive result of blood cultures; F = female; M = male; P = positive; N = negative.

Recommended cut-off values are 120 AU/mL for both assays; 80 to 120 AU/mL is considered as undetermined results. All the data were analyzed anonymously and only routine diagnostic samples were used in this study, having no influence in therapeutic decisions.
RESULTS

Diagnostic performance of the anti-mannan IgG ELISA assay

Serum samples of 40 candidemia patients and 261 controls were tested. Among the 40 candidemia patients, anti-mannan IgG were positive in 13/19 of candidemia patients with *C. albicans* infection, 6/8 with *C. tropicalis*, 4/6 with *C. parapsilosis*, 2/5 with *C. glabrata*, 1/1 with *C. krusei* and 1/1 with *C. lusitaniae*. As for the undetermined results, they were considered to be positive and negative, respectively. If the undetermined results were considered as positive results, the IgG ELISA assay had a sensitivity of 0.75 (0.58-0.87) and an overall specificity of 0.91 (0.87-0.94). If the undetermined results were considered negative, the IgG ELISA assay had a sensitivity of 0.68 (0.51-0.81) and an overall specificity of 0.94 (0.90-0.97) (Table 1). The specific concentrations of anti-mannan IgG were shown in Table 2 and Figure 1.

Table 3 - Characteristics of control group 1 (without colonization) and control group 2 (with colonization).

| Patient/parameter          | control group 1 | control group 2 |
|----------------------------|-----------------|-----------------|
| Median age, y (range)      | 44(31-52)       | 69 (63-75)      |
| Gender (men/women)         | 109/104         | 30/18           |
| Cardiovascular disease     | 31/213          | 6/48            |
| Renal disease              | 20/213          | 4/48            |
| Lung disease               | 9/213           | 19/48           |
| Brain disease              | 29/213          | 8/48            |
| Neurological disease       | 3/213           | -               |
| Hypertension               | 4/213           | 3/48            |
| Biliary tract disease      | 9/213           | 2/48            |
| Trauma                     | 7/213           | 2/48            |
| Fever                      | 1/213           | 1/48            |
| Digestive tract disease    | 19/213          | 1/48            |
| Endocrine disease          | 4/213           | -               |
| Eye diseases               | 3/213           | -               |
| Bone disease               | 6/213           | -               |
| others                     | 13/213          | 2/48            |
| Healthy control            | 55/213          | -               |

Figure 1 - The concentration of anti-mannan IgG and IgM antibodies in candidemia patients and controls. The dotted lines are the cut-off values of the assays (80AU/mL and 129AU/mL); the continuous lines are the median of the concentrations of the antibodies in each group.
1/1 with *C. lusitaniae*. If the undetermined results were considered as positive results, the IgM ELISA assay had a sensitivity of 0.80 (0.64-0.90) and a specificity of 0.97 (0.94-0.99). If the undetermined results were considered as negative results, the IgM ELISA assay had a sensitivity of 0.78 (0.61-0.89) and a specificity of 0.98 (0.95-0.99) (Table 1). The specific concentrations of anti-mannan IgM were shown in Table 2 and Figure 1.

**Diagnostic performance of the combined detection of the two assays**

In the combined detection of IgG and IgM assays, serum samples with positive result (≥120 AU/mL) of single or both assays were regarded as positive. Anti-mannan IgG and/or IgM were positive in 19/19 of candidemia patients with *C. albicans* infection, 7/8 with *C. tropicalis*, 5/6 with *C. parapsilosis*, 4/5 with *C. glabrata*, 1/1 with *C. krusei*, 1/1 with *C. lusitaniae*. The sensitivity of the combined detection of two assays for diagnosing candidemia was 0.93 (0.79-0.98) and the specificity was 0.93 (0.89-0.95) (Table 1).

**DISCUSSION**

Candidemia is one of the most common bloodstream fungal infections whose diagnosis is based mainly on blood cultures. However, blood cultures lack sensitivity (ranging from 21% to 71% in different studies) and its turnaround time is limited. As is known, even a mere 12 hours of diagnostic delay may expose infected individuals to a higher risk of disability and mortality, so the timely diagnosis is of cardinal importance.

Parra-Sánchez et al. indicated that the sensitivity of the *C. albicans* germ-tube specific IgG antibody assay ranged from 61.1% to 85.7% and the specificity ranged from 75.8% to 80.3%. Mattsby-Baltzer et al. study reported that IgG2 anti-phosphopeptidomannan antibody is another biomarker with 88% sensitivity and 94% specificity in invasive candidiasis, but no IgG2 antibody response was observed in *C. parapsilosis* and *C. albicans* infections. White et al. described that the sensitivity and specificity of a (1-3)-β-D-Glucan (D-BDG) assay were 90.7% and 73.4% in the diagnosis of invasive fungal disease, when optimal positivity threshold was 70 pg/mL. Alam et al. reinforced the diagnostic value of semi-nested PCR (snPCR), which can detect DNA of different *Candida* species in serum samples of over 50% of the clinically suspected patients without positive blood cultures, while the combination of mannan and D-BDG is necessary to eliminate false positive reactions.

Antibodies against constituents of *Candida* are also sensitive biomarkers. As is known, antibodies to *Candida* class IgA, IgM, IgG and IgE, and different antibody isotypes differ in diagnostic performance. A study has shown that *Candida albicans* could significantly decrease the secretion of IgG in a dose-dependent manner while enhancing IgM. In addition, the difference in antibody levels between patients and healthy controls is more significant for anti-*Candida* receptor 3-related protein IgM than for IgG, and atopic dermatitis patients were found to have abnormalities in the production of IgG antibodies against *Candida albicans*. To sum up, IgM is probably more useful than IgG for the diagnosis of candidemia.

In studies with different designs and populations, the clinical value of anti-mannan assays in the diagnosis of *Candida* infection had variable sensitivity (40% to 70%) and specificity (50% to 80%). Differences in diagnostic performance may be attributed to inclusion and exclusion criteria, different sample structure including number of cases enrolled, grouping mode, baseline characteristics and distribution of isolated *Candida* spp. In Mikulska et al. meta-analysis, the sensitivity and specificity of the anti-mannan assays for invasive candidiasis were 59% and 86%, and the sensitivity and specificity for a combined mannan/anti-mannan assay were 83% and 86%. Meta-analysis can solve the problem of small sample size, yet it may suffer from publication bias. Many of these studies did not mention which isotype of antibody was used.

In the present study, we evaluated the diagnostic performance of a new anti-mannan IgM and IgG assays for candidemia. All the enrolled cases were candidemia patients without significantly abnormal immune function and this is the most likely explanation for the better diagnostic performance (higher sensitivity) than in other studies. Regarding the discordant results, only three confirmed that candidemia patients had negative results in both assays, including one with *C. tropicalis*, one with *C. parapsilosis* and one with *C. glabrata*. Anti-mannan IgM assay had a better diagnostic performance than the IgG assay, with higher sensitivity and specificity. The combined assays in our study had relatively high sensitivity and there was a high concordance with the infections status. Among all the 40 candidemia patients, the serum sample collection of 23 candidemia patients took place before getting the positive results of blood cultures. We obtained positive detection of IgM antibodies in 21 of them, while IgG was detected in 15 of them. In the combined detection of IgG and IgM, only one of these 23 patients (infected with *C. parapsilosis*) had both, IgG and IgM negative antibodies. The combined assays can help to detect infections earlier because they can be positive as long as 4 days prior to blood cultures. Chumpitazi et al. found that mannan is also a biomarker appearing early in
the development of candidemia. However, its specificity was 86% and its sensitivity was 77% in the meta-analysis. Although both, the sensitivity and specificity of the assays in our study showed better diagnostic performances, there were still several nonspecific results in the control groups, some of which had high antibody titers. According to the manufacturer’s instructions, these assays are qualitative rather than quantitative with cut-off values of 80 AU/mL and 120 AU/mL, so that positive or negative results are more valuable for clinical practice. In Clancy et al.24 review, invasive candidiasis patients with negative blood cultures were called the “missing 50%”, which is one of the possible reasons for the nonspecific results with high titers especially in patients with Candida colonization. However, whether some of the patients without any evidence of infection had positive result is still uncertain. From the results, we suggested that candidemia cannot be judged only according to high titers of anti-mannan IgG or IgM. A correct diagnosis must be made on the basis of suggestive clinical symptoms, presence of risk factors for candidemia (such as abdominal surgery, central venous catheter, mechanical ventilation, etc). Unselected screening of anti-mannan for Candida infections in similar settings is inappropriate, while using anti-mannan as a complementary test to blood culture results may be preferred in clinically suspected candidemia patients and cases with high risk based on our study results.

CONCLUSION

Our study has shown that anti-mannan IgM and IgG assays are useful to assist clinicians in making an earlier diagnosis of candidemia and differentiating Candida colonization from candidemia in patients without significantly abnormal immune function. The tests have shown a high negative predictive value (>85%) and can be used to rule out infections, as part of diagnostic strategies to establish the absence of candidemia, reducing the unwarrant use of antifungal agents in patients.

AUTHORS’ CONTRIBUTIONS

Concept, design: Ying Ma; literature search, clinical studies, experimental studies: Mei Kang; data acquisition, data analysis, statistical analysis: Ziwei Kuang, Dongdong Li; manuscript preparation, manuscript editing, and manuscript review: Yanming Meng, Tingting Wang.

CONFLICT OF INTERESTS

No potential conflict of interests relevant to this article were reported.

REFERENCES

1. Li Y, Sun L, Lu C, Gong Y, Li M, Sun S. Promising antifungal targets against Candida albicans based on ion homeostasis. Front Cell Infect Microbiol. 2018;8:286.
2. Ahmad A, Wani MY, Patel M, Sobral AJ, Duse AG, Aqlan FM, et al. Synergistic antifungal effect of cyclized chalcone derivatives and fluconazole against Candida albicans. Medchemcomm. 2017;8:2195-207.
3. Patin EC, Jones AV, Thompson A, Clement M, Liao CT, Griffiths JS, et al. IL-27 induced by select Candida spp. via TLR7/NOD2 signaling and IFN-beta production inhibits fungal clearance. J Immunol. 2016;197:208-21.
4. Arendrup MC, Broun B, Christensen JJ, Fuursted K, Johansen HK, Kjaeldgaard P, et al. National surveillance of fungemia in Denmark (2004 to 2009). J Clin Microbiol. 2011;49:325-34.
5. Arendrup MC, Fuursted K, Gahn-Hansen B, Schonheyder HC, Knudsen JD, Jensen IM, et al. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microbiol Infect. 2008;14:487-94.
6. Cuenca-Estrella M, Verweij PE, Arendrup MC, Arikan-Akdagli S, Bille J, Donnelly JP, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect. 2012;18 Suppl 7:9-18.
7. Morad HO, Wild AM, Wiehr S, Davies G, Maurer A, Pichler BJ, et al. Pre-clinical imaging of invasive Candidiasis using ImmunoPET/MR. Front Microbiol. 2018;9:1996.
8. Fuchs BB, Eatemadpour S, Martel-Foley JM, Stott S, Toner M, Mylonakis E. Rapid isolation and concentration of pathogenic fungi using inertial focusing on a chip-based platform. Front Cell Infect Microbiol. 2019;9:27.
9. Turecka K, Chylewska A, Kawiak A, Waleron KF. Antifungal activity and mechanism of action of the Co(III) coordination complexes with diamine chelate ligands against reference and clinical strains of Candida spp. Front Microbiol. 2018;9:1594.
10. Parra-Sánchez M, Zakariya-Yousef Brelav I, Castro Méndez C, García-Rey S, Loza Vázquez A, Úbeda Iglesias A, et al. Candida albicans germ-tube antibody: evaluation of a new automatic assay for diagnosing invasive candidiasis in ICU patients. Mycopathologia. 2017;182:645-52.
11. Matusby-Baltzer I, Pinel C, Yugueros Marcos J, Kondori N, Potton L, Thiebaut-Bertrand A, et al. IgG1 anti-cell wall and IgG2 anti-phosphopeptidomannan antibodies in the diagnosis of invasive candidiasis and heavy Candida colonization. Med Mycol. 2015;53:725-35.
12. White PL, Price JS, Posso RB, Barnes RA. An evaluation of the performance of the Dynamiker® Fungus (1-3)-β-D-Glucan assay to assist in the diagnosis of invasive aspergillosis, invasive candidiasis and Pneumocystis pneumonia. Med Mycol. 2017;55:843-50.
13. Alam FF, Mustafa AS, Khan ZU. Comparative evaluation of (1,3)-β-D-glucan, mannan and anti-mannan antibodies, and Candida species-specific snPCR in patients with candidemia. BMC Infect Dis. 2007;7:103.

14. Capodicasa C, Catellani M, Moscetti I, Bromuro C, Chiani P, Torosantucci A, et al. Comparative analysis of plant-produced, recombinant dimeric IgA against cell wall β-glucan of pathogenic fungi. Biotechnol Bioeng. 2017;114:2729-38.

15. Piliponsky AM, Acharya M, Shubin NJ. Mast cells in viral, bacterial, and fungal infection immunity. Int J Mol Sci. 2019;20:E2851

16. Huang F, Song Y, Chen W, Liu Q, Wang Q, Liu W, et al. Effects of Candida albicans infection on defense effector secretion by human oral mucosal epithelial cells. Arch Oral Biol. 2019;103:55-61.

17. Paulovicová E, Bujdákova H, Chupácova J, Paulovicová L, Kertys P, Hrubisko M. Humoral immune responses to Candida albicans complement receptor 3-related protein in the atopic subjects with vulvovaginal candidiasis. Novel sensitive marker for Candida infection. FEMS Yeast Res. 2015;15:fou001.

18. Javad G, Taheri Sarvtin M, Hedayati MT, Hajheydari Z, Yazdani J, Shokohi T. Evaluation of candida colonization and specific humoral responses against candida albicans in patients with atopic dermatitis. Biomed Res Int. 2015;2015:849206.

19. León C, Ruiz-Santana S, Saavedra P, Castro C, Loza A, Zakariya I, et al. Contribution of Candida biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU patients with severe abdominal conditions. Crit Care. 2016;20:149.

20. Held J, Kohlberger I, Rappold E, Busse Grawitz A, Häcker G. Comparison of (1->3)-β-D-glucan, mannan/anti-mannan antibodies, and Cand-Tec Candida antigen as serum biomarkers for candidemia. J Clin Microbiol. 2013;51:1158-64.

21. Clancy CJ, Nguyen MH. Non-culture diagnostics for invasive candidiasis: promise and unintended consequences. J Fungi (Basel). 2018;4:E27.

22. Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care. 2010;14:R222.

23. Chumpitazi BF, Lebeau B, Faure-Cognet O, Hamidfar-Roy R, Timsit JF, Pavese P, et al. Characteristic and clinical relevance of Candida mannan test in the diagnosis of probable invasive candidiasis. Med Mycol. 2014;52:462-71.

24. Clancy CJ, Nguyen MH. Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013;56:1284-92